Citigroup
RANI icon

Citigroup’s Rani Therapeutics RANI Stock Holding History

Citigroup’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01K Sell
2,643
-83
-3% -$74 ﹤0.01% 5376
2026
Q1 		$2K Sell
2,726
-50,369
-95% -$64.3K ﹤0.01% 5424
2025
Q4 		$71.7K Buy
+53,095
New +$80.1K ﹤0.01% 4452
2025
Q2 		– Sell
-313
Closed -$394 – 5855
2025
Q1 		$394 Buy
+313
New +$463 ﹤0.01% 5398
2022
Q4 		– Sell
-295
Closed -$3K – 5924
2022
Q3 		$3K Sell
295
-82
-22% -$869 ﹤0.01% 5408
2022
Q2 		$4K Sell
377
-45
-11% -$517 ﹤0.01% 5706
2022
Q1 		$6K Sell
422
-442
-51% -$7.33K ﹤0.01% 5767
2021
Q4 		$14K Buy
+864
New +$19.6K ﹤0.01% 5492

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Citigroup's RANI Position: Q2 2026 in Review

Citigroup reduced its Rani Therapeutics (RANI) stake by 3% in Q2 2026, selling an estimated $74 and leaving 2,643 shares worth $2.01K. The position accounts for ﹤0.01% of the portfolio, ranked #5376.

Citigroup first reported a position in RANI in Q4 2021 and has held it in 8 quarters since. The position peaked at $71.7K in Q4 2025. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Citigroup held 2,643 shares of Rani Therapeutics worth $2.01K as of Q2 2026.
  • Citigroup sold 83 Rani Therapeutics shares in Q2 2026, an estimated $74.
  • Rani Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5376 holding.
  • Citigroup first reported a position in Rani Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • Citigroup's Rani Therapeutics position peaked at $71.7K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.